Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.

Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W.

Br J Cancer. 2018 Jun 8. doi: 10.1038/s41416-018-0142-6. [Epub ahead of print]

PMID:
29880907
2.

Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer.

Jeitany M, Leroy C, Tosti P, Lafitte M, Le Guet J, Simon V, Bonenfant D, Robert B, Grillet F, Mollevi C, El Messaoudi S, Otandault A, Canterel-Thouennon L, Busson M, Thierry AR, Martineau P, Pannequin J, Roche S, Sirvent A.

EMBO Mol Med. 2018 Apr;10(4). pii: e7918. doi: 10.15252/emmm.201707918.

3.

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.

Viala M, Vinches M, Alexandre M, Mollevi C, Durigova A, Hayaoui N, Homicsko K, Cuenant A, Gongora C, Gianni L, Tosi D.

Br J Cancer. 2018 Mar 6;118(5):679-697. doi: 10.1038/bjc.2017.473. Epub 2018 Feb 13.

PMID:
29438365
4.

Reconciliation of patient/doctor vocabulary in a structured resource.

Tapi Nzali MD, Aze J, Bringay S, Lavergne C, Mollevi C, Optiz T.

Health Informatics J. 2018 Jan 1:1460458217751014. doi: 10.1177/1460458217751014. [Epub ahead of print]

PMID:
29332530
5.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

PMID:
29123966
6.

Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials.

Barbieri A, Peyhardi J, Conroy T, Gourgou S, Lavergne C, Mollevi C.

BMC Med Res Methodol. 2017 Sep 26;17(1):148. doi: 10.1186/s12874-017-0410-9. Review.

7.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M.

Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330.

PMID:
28911069
8.

What Patients Can Tell Us: Topic Analysis for Social Media on Breast Cancer.

Tapi Nzali MD, Bringay S, Lavergne C, Mollevi C, Opitz T.

JMIR Med Inform. 2017 Jul 31;5(3):e23. doi: 10.2196/medinform.7779.

9.

Antibody targeting of claudin-1 as a potential colorectal cancer therapy.

Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M.

J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046-017-0558-5.

10.

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.

Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P.

Eur J Cancer. 2017 May;76:68-75. doi: 10.1016/j.ejca.2017.02.003. Epub 2017 Mar 8.

PMID:
28284171
11.

Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.

Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P.

Cancer Med. 2016 Apr;5(4):607-16. doi: 10.1002/cam4.621. Epub 2016 Jan 27.

12.

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.

Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ.

BMC Cancer. 2015 Dec 18;15:986. doi: 10.1186/s12885-015-1977-3.

13.

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, Del Conte G, Durigova A, Hayaoui N, Gourgou S, Gianni L, Mollevi C.

J Clin Oncol. 2015 Jul 1;33(19):2158-65. doi: 10.1200/JCO.2014.58.1082. Epub 2015 May 26. Review.

PMID:
26014300
14.

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A.

Oncotarget. 2015 May 20;6(14):12796-808.

15.

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Ezzalfani M, Dugué A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Médioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X.

Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2. Review. French.

PMID:
25609488
16.

Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.

Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, Saint-Aubert B, Quenet F, Rouanet P, Mollevi C.

Gynecol Oncol. 2014 Nov;135(2):223-30. doi: 10.1016/j.ygyno.2014.09.002. Epub 2014 Sep 16.

PMID:
25220627
17.

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C.

Oncotarget. 2014 Aug 30;5(16):7138-48.

18.

Breast cancer and quality of life: medical information extraction from health forums.

Opitz T, Aze J, Bringay S, Joutard C, Lavergne C, Mollevi C.

Stud Health Technol Inform. 2014;205:1070-4.

PMID:
25160353
19.

In-cell intrabody selection from a diverse human library identifies C12orf4 protein as a new player in rodent mast cell degranulation.

Mazuc E, Guglielmi L, Bec N, Parez V, Hahn CS, Mollevi C, Parrinello H, Desvignes JP, Larroque C, Jupp R, Dariavach P, Martineau P.

PLoS One. 2014 Aug 14;9(8):e104998. doi: 10.1371/journal.pone.0104998. eCollection 2014.

20.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M.

Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.

PMID:
24658074
21.

Specific extracellular matrix remodeling signature of colon hepatic metastases.

Del Rio M, Mollevi C, Vezzio-Vie N, Bibeau F, Ychou M, Martineau P.

PLoS One. 2013 Sep 4;8(9):e74599. doi: 10.1371/journal.pone.0074599. eCollection 2013.

22.

Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C.

Cancer Res. 2011 Feb 1;71(3):1041-9. doi: 10.1158/0008-5472.CAN-10-2726. Epub 2010 Dec 15.

23.

Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.

Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H.

Clin Cancer Res. 2004 Sep 1;10(17):5769-76.

Supplemental Content

Loading ...
Support Center